Abstract
Pancreas cancer confounds patient and physician alike. With an almost identical annual incidence and mortality, the disease has heretofore thwarted attempts to cure and even contain it. The approach to the patient with pancreas cancer is the same as for any cancer: detect it early, diagnose it accurately and eradicate it through a combination of surgery and chemical and radiotherapies. However, cancer of this organ eludes early detection, runs the risk of significant collateral injury when attempting to biopsy it for diagnosis, and resists all current forms of conventional chemotherapy and radiation. Moreover, the disease is as difficult to study in patients as it is to treat. Although classical experimental model systems have yielded significant information on genetic mutations of interest, they have not proved as useful in screening for drugs likely to be effective in patients. Mammalian model systems that faithfully mimic the full spectrum of the human disease from inception to invasion are needed. This chapter describes an integrated translational approach to developing and testing early detection, molecular diagnostic, chemopreventive and therapeutic strategies using state-of-the-art genetically engineered mouse models.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adsay NV (2005) Pathological classification of cystic neoplasms of the pancreas. In: Von Hoff DD, Evans DB, Hruban RH (eds) Pancreatic Cancer. Jones and Bartlett Publishers, Sudbury, pp 716–756
Aguirre AJ, Bardeesy N, Sinha M et al (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112–3126
Apte MV, Haber PS, Applegate TL et al (1998) Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 43:128–133
Apte MV, Park S, Phillips PA et al (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29:179–187
Bachem MG, Schneider E, Gross H et al (1998) Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115:421–432
Bardeesy N, Aguirre AJ, Chu GC et al (2006a) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103:5947–5952
Bardeesy N, Cheng KH, Berger JH et al (2006b) Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20:3130–3146
Berlin JD (2007) Adjuvant therapy for pancreatic cancer: to treat or not to treat? Oncology (Williston Park) 21:712–718; discussion 720, 725–716, 730
Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54
Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
Clark CE, Hingorani SR, Mick R et al (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67:9518–9527
DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68:8643–8653
Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417–429
Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848
Faca VM, Song KS, Wang H et al (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5:e123
Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–416
Funahashi H, Satake M, Dawson D et al (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67:7068–7071
Grippo PJ, Sandgren EP (2005) Modeling pancreatic cancer in animals to address specific hypotheses. Methods Mol Med 103:217–243
Guerra C, Schuhmacher AJ, Canamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364
Heldin CH, Rubin K, Pietras K et al (2004) High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 4:806–813
Hermann PC, Huber SL, Herrler T et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323
Hertel LW, Boder GB, Kroin JS et al (1990) Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 50:4417–4422
Hingorani SR (2005) Modeling pancreatic ductal adenocarcinoma in the mouse. In: Gress TM, Neoptolemos JP, Lemoine NR, Real FX (eds) Exocrine pancreas cancer. Felsenstein CCCP Publishing, Hannover, pp 152–171
Hingorani SR (2007) Location, location, location: precursors and prognoses for pancreatic cancer. Gastroenterology 133:345
Hingorani SR (2008) From inception to invasion: modeling pathways to pancreatic cancer. In: Lowy AM, Leach SD, Philip PA (eds) Pancreatic Cancer. Springer, US, pp 159–179
Hingorani SR, Tuveson DA (2003) Targeting oncogene dependence and resistance. Cancer Cell 3:414–417
Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450
Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–483
Hruban RH (2006) Tumors of the pancreas. In: Hruban RH, Klimstra DS, Pitman MB (eds) Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DC
Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586
Hruban RH, Takaori K, Klimstra DS et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977–987
Hruban RH, Adsay NV, Albores-Saavedra J et al (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66:95–106
Huxham LA, Kyle AH, Baker JH et al (2004) Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 64:6537–6541
Ijichi H, Chytil A, Gorska AE et al (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20:3147–3160
Ikeda N, Adachi M, Taki T et al (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79:1553–1563
Izeradjene K, Hingorani SR (2007) Targets, trials, and travails in pancreas cancer. J Natl Compr Canc Netw 5:1042–1053
Izeradjene K, Combs C, Best M et al (2007) Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11:229–243
Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806
Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436
Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM (2007) A double-blind, placebo-controlled randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 (Abstract). American Society of Clinical Oncology Gastointestinal Cancers Symposium, 19–21. Orlando, FL
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715
Lankelma J, Dekker H, Luque FR et al (1999) Doxorubicin gradients in human breast cancer. Clin Cancer Res 5:1703–1707
Leach SD (2004) Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 5:7–11
Li C, Heidt DG, Dalerba P et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037
Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186–1197
Maitra A, Fukushima N, Takaori K et al (2005) Precursors to invasive pancreatic cancer. Adv Anat Pathol 12:81–91
Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966
Mulcahy MF (2007) Adjuvant therapy for pancreas cancer: advances and controversies. Semin Oncol 34:321–326
Omary MB, Lugea A, Lowe AW et al (2007) The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117:50–59
Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598
Radisky D, Hagios C and Bissell MJ (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11:87–95
Roberts TG Jr, Goulart BH, Squitieri L et al (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140
Rustgi AK (2006) The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes Dev 20:3049–3053
Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32
Tannock I (1978) Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62:1117–1133
Tuveson DA, Hingorani SR (2005) Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 70:65–72
Von Hoff DD, Hruban RH, Evans DB (2005) Pancreatic cancer. Jones and Bartlett, Sudbury, MA
Walter K, Omura N, Hong SM et al (2008) Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biol Ther 7:882–888
Waterston RH, Lindblad-Toh K, Birney E et al (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420:520–562
Weinstein IB (2002) Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297:63–64
Yeh JJ, Der CJ (2007) Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets 11:673–694
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hingorani, S. (2010). A New Preclinical Paradigm for Pancreas Cancer. In: Han, H., Grippo, P. (eds) Drug Discovery in Pancreatic Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1160-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1160-5_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1159-9
Online ISBN: 978-1-4419-1160-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)